| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
SEQUA Stock Overview
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure.
Sequana Medical Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.72 |
| 52 Week High | €9.80 |
| 52 Week Low | €5.26 |
| Beta | 1.14 |
| 1 Month Change | -12.27% |
| 3 Month Change | -11.46% |
| 1 Year Change | -33.18% |
| 3 Year Change | -7.14% |
| 5 Year Change | n/a |
| Change since IPO | -32.07% |
Recent News & Updates
Shareholder Returns
| SEQUA | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | -6.8% | 1.3% | -1.0% |
| 1Y | -33.2% | -11.3% | -4.6% |
Return vs Industry: SEQUA underperformed the Belgian Medical Equipment industry which returned -12.6% over the past year.
Return vs Market: SEQUA underperformed the Belgian Market which returned -3.6% over the past year.
Price Volatility
| SEQUA volatility | |
|---|---|
| SEQUA Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in BE Market | 8.0% |
| 10% least volatile stocks in BE Market | 3.2% |
Stable Share Price: SEQUA is more volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SEQUA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 60 | Ian Crosbie | https://www.sequanamedical.com |
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company’s products include alfapump system, an implantable pump system for the treatment of refractory ascites due to liver cirrhosis and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal (DSR) to manage fluid overload in heart failure patients. It operates in Switzerland, Germany, France and internationally.
Sequana Medical Fundamentals Summary
| SEQUA fundamental statistics | |
|---|---|
| Market Cap | €135.83m |
| Earnings (TTM) | -€23.62m |
| Revenue (TTM) | €370.50k |
366.7x
P/S Ratio-5.8x
P/E RatioIs SEQUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEQUA income statement (TTM) | |
|---|---|
| Revenue | €370.50k |
| Cost of Revenue | €76.66k |
| Gross Profit | €293.84k |
| Other Expenses | €23.91m |
| Earnings | -€23.62m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 08, 2022
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 79.31% |
| Net Profit Margin | -6,373.84% |
| Debt/Equity Ratio | -930.8% |
How did SEQUA perform over the long term?
See historical performance and comparisonValuation
Is Sequana Medical undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
In this section, we usually try to help investors determine whether Sequana Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sequana Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Future Growth
How is Sequana Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-4.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SEQUA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SEQUA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SEQUA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SEQUA's revenue (75.5% per year) is forecast to grow faster than the Belgian market (0.7% per year).
High Growth Revenue: SEQUA's revenue (75.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SEQUA's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Sequana Medical performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-15.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SEQUA is currently unprofitable.
Growing Profit Margin: SEQUA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SEQUA is unprofitable, and losses have increased over the past 5 years at a rate of 15.6% per year.
Accelerating Growth: Unable to compare SEQUA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SEQUA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.1%).
Return on Equity
High ROE: SEQUA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Financial Health
How is Sequana Medical's financial position?
Financial Health Score
0/6Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SEQUA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SEQUA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SEQUA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: SEQUA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SEQUA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SEQUA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.4% each year
Dividend
What is Sequana Medical current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SEQUA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SEQUA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SEQUA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SEQUA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SEQUA has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Ian Crosbie
6.33yrs
Tenure
Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV since 2016 and serves as its Director since 2019. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December...
Leadership Team
Experienced Management: SEQUA's management team is considered experienced (3.1 years average tenure).
Board Members
Experienced Board: SEQUA's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.8%.
Top Shareholders
Company Information
Sequana Medical NV's employee growth, exchange listings and data sources
Key Information
- Name: Sequana Medical NV
- Ticker: SEQUA
- Exchange: ENXTBR
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €135.830m
- Shares outstanding: 23.75m
- Website: https://www.sequanamedical.com
Number of Employees
Location
- Sequana Medical NV
- AA Tower
- Technologiepark 122
- Gent
- East Flanders
- 9052
- Belgium
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/13 00:00 |
| End of Day Share Price | 2022/05/13 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.